Drugs / BMS-852927
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01651273 | Nov 2012 → Jun 2013 | hyperlipidemia | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-852927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651273 ↗ |
| Known as | EXEL-04541041 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3945199 ↗ |
| Known as | XL-041 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3945199 ↗ |
| Known as | XL-652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3945199 ↗ |
| Modality | Small molecule | — CHEMBL3945199 ↗ |
| Route | Oral | “Capsules, Oral” NCT01651273 ↗ |
| Target | NR1H2 | “LXR-beta modulator” CHEMBL3945199 ↗ |
| Target | NR1H3 | “LXR-alpha modulator” CHEMBL3945199 ↗ |